The FDA approved a new Alzheimer's treatment called donanemab, aiming to slow brain decline in early-stage patients, following setbacks and delays. Eli Lilly expects the drug, branded as Kisunla, to be available within weeks.
Donanemab, an anti-amyloid monoclonal antibody, targets and removes amyloid plaques linked to Alzheimer's disease. Trials showed patients could stop the drug after six months if amyloid levels improved.
Collection
[
|
...
]